Group 1 - Core viewpoint: Bailin Ke Medical Technology (Shanghai) Co., Ltd. has completed its IPO counseling record with the Shanghai Securities Regulatory Bureau and plans to list on the A-share market, with CITIC Securities as the counseling institution [1] - Company establishment: Bailin Ke was established on September 10, 2021, with a registered capital of 360 million yuan, and is a high-tech group enterprise providing process solutions for the life sciences sector [1] - Business focus: The company specializes in the research and manufacturing of key process equipment and consumables for the production of recombinant protein drugs, vaccines, antibody drugs, cell therapy, gene therapy, and other biological products [1] Group 2 - Sales and service points: Bailin Ke has sales service points in cities including Beijing, Shanghai, Guangzhou, Chengdu, Suzhou, Wuhan, Jinan, and Changchun, and has established a research and application demonstration center in Suzhou [2] - International expansion: The company has opened subsidiaries in Germany and Singapore to support its international business expansion strategy [2] - Shareholder structure: The controlling shareholder is Hainan Bailin Ke Technology Investment Center (Limited Partnership), holding a direct stake of 27.8%, with other investors including KKR, Yahui Investment, Qingsong Capital, Shenzhen Capital Group, and Haiwang Capital [2]

Core Viewpoint - Sartorius achieved a sales revenue of €3.538 billion in the fiscal year 2025, representing a year-on-year growth of 7.6% [2][3] Group Business Development - The sales revenue growth was driven by the Bioprocess Solutions segment, which generated €2.865 billion, up 9.5% year-on-year, primarily due to strong demand for high-margin consumables like filters and single-use bags [2][3][7] - The Laboratory Products and Services segment reported sales of €673 million, with a modest growth of 0.2% year-on-year [2][10] - The overall sales growth was supported by a basic EBITDA increase of 11.2%, reaching €1.052 billion, with a profit margin improvement from 28.0% to 29.7% [4] Regional Performance - All regions contributed to sales growth: EMEA region grew by 5.8% to €1.467 billion, the Americas increased by 8.9% to €1.251 billion, and the Asia-Pacific region also saw an 8.9% rise, reaching €820 million [4] Financial Performance - Basic net profit rose by 18.2% to €331 million, with basic earnings per share increasing to €4.78 from €4.05 [5] - The company’s employee count increased to 14,042, reflecting a growth of 514 employees compared to the end of 2024 [5] - The net asset ratio improved to 39.8% from 38.6% in 2024, and the net debt to basic EBITDA ratio decreased to 3.55 from 3.96 [5] Long-term Investment and Infrastructure - Sartorius continued to invest in long-term growth, with total capital expenditure reaching €442 million, representing 12.5% of sales revenue [6] - Key expansions included the bioprocess technology production facility in France and the membrane and filter production line in Germany [6] Bioprocess Solutions Segment - This segment accounted for over 75% of total sales, achieving a significant growth of 9.5% to €2.865 billion, driven by strong demand for consumables [7][8] - Basic EBITDA for this segment increased by 15.2% to €907 million, with a profit margin rise to 31.7% [7] Laboratory Products and Services Segment - This segment showed resilience in a challenging market, with sales reaching €673 million, recovering to last year's levels by December [10] - The segment's basic EBITDA decreased by 8.6% to €145 million, with a profit margin of 21.5% [10][11] 2026 Performance Guidance - For fiscal year 2026, Sartorius expects continued profitable growth, with sales revenue projected to increase by approximately 5% to 9% [12][14] - The Bioprocess Solutions segment is anticipated to grow by 6% to 10%, while the Laboratory Products and Services segment is expected to grow by 2% to 6% [14]